Mekinist & Tafinlar Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of GlaxoSmithKline’s metastatic melanoma therapies Tafinlar (dabrafenib) and Mekinist (tramatenib).